GSK Announces Shareholders Meeting to Discuss Novartis Deal
GSK and Novartis announced a meeting on Dec. 18, 2014 to discuss the $20 billion asset swap between the two companies.
In April, Novartis and GlaxoSmithKline (GSK) announced that they would swap assets in which Novartis would acquire GSK’s oncology products business, and GSK would acquire Novartis’ vaccines business (not including the flu vaccine). The two groups would trade more than $20 billion in assets, combined.
On Nov. 24, 2014, the companies announced a general meeting to be held on Dec. 18, 2014 where the companies will seek shareholder approval for the proposed transaction. GSK posted the “circular” to shareholders and notice of a general meeting in relation to the transaction on its website.
Source: GSK
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
